pharmaphorum14m
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its ...
Novo Nordisk, Lilly Stocks Are Falling. A Rival Weight-Loss Drug Is on the Way.
Shares of Novo Nordisk and Eli Lilly slipped in premarket trading Wednesday after Roche said it had landed a $5.3 billion ...
Roche And Zealand Team Up To Develop Petrelintide
Roche & Zealand Pharma join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. See why this ...
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Key Takeaways Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly.The Swiss ...